CELCHIGH SIGNALFINANCIAL10-K

CELC's cash burn accelerated substantially while the company raised significant capital, indicating intensified Phase 3 clinical trial activities.

The company appears to be in an aggressive spending phase for its Phase 3 gedatolisib trials, with operating cash burn increasing meaningfully while R&D expenses grew 39%. Despite raising substantial capital that nearly doubled total assets, the accelerated burn rate suggests investors should monitor cash runway closely as the company advances through expensive late-stage clinical development.

Comparing 2026-03-26 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

CELC executed a major capital raise that nearly doubled its asset base to $466.6M, providing significant liquidity for operations. However, the company's cash burn accelerated substantially as operating losses widened meaningfully, driven by a 39% increase in R&D spending to support Phase 3 clinical trials. The financial profile reflects a biotech company in intensive late-stage development mode, burning cash at an elevated rate despite having strengthened its balance sheet through recent financing activities.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+90.4%
$244.6M→$465.7M

Current assets grew 90.4% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+90.3%
$245.1M→$466.6M

Asset base grew 90.3% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
-83.6%
-$83.5M→-$153.3M

Operating cash flow fell 83.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
-58.4%
-$111.8M→-$177.0M

Net income declined 58.4% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-52%
-$113.3M→-$172.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Liabilities
Balance Sheet
+39.2%
$31.7M→$44.2M

Current liabilities surged 39.2% — significant near-term obligations; verify ability to meet short-term debt.

R&D Expense
P&L
+39.1%
$104.2M→$145.0M

R&D investment increased 39.1% — signals commitment to future product development, though near-term margin impact.

Total Debt
Balance Sheet
+30.9%
$105.1M→$137.5M

Debt increased 30.9% — substantial leverage increase; assess whether deployed for growth or covering losses.

Stockholders Equity
Balance Sheet
-13%
$115.6M→$100.6M

Equity decreased 13% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-31
ADDED
As of March 17, 2026, there were 48,336,675 shares of the registrant s common stock outstanding.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 91 Item 9A.
Forward-looking statements may include, among other things, statements relating to: our clinical trial plans and the estimated timelines and costs for such trials; our plans to develop and commercialize our products, and our expectations about the market opportunity for gedatolisib in the U.S.
( Pfizer ) with respect to gedatolisib; our expectations regarding the future payments that may be owed to Pfizer under our license agreement with them; our beliefs with respect to the potential rate and degree of market acceptance and clinical utility of gedatolisib, both in the U.S.
and internationally; our revenue expectations; our expectations regarding business development activities, including collaborations with pharmaceutical companies; our plans with respect to pricing in the U.S.
+7 more — sign up free →
REMOVED
As of March 24, 2025, there were 37,839,392 shares of the registrant s common stock outstanding.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure s 67 Item 9A.
We have a limited operating history and we may never generate revenue or profit; Our inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize our drug candidate, gedatolisib; Future financing activities could dilute the percentage ownership of our stockholders and could cause our stock price to fall, or could result in operating or other restrictions; We are currently conducting and will continue to conduct clinical trials.
Clinical trials are expensive and complex with uncertain outcomes, which may prevent or delay commercialization of our products; Our near-term revenue prospects depend on the success of our initial drug product, gedatolisib.
Because all drugs can have adverse effects, the data from our Phase 3 clinical study must demonstrate to the satisfaction of the FDA and other health authorities that the benefits of gedatolisib in combination with palbociclib and fulvestrant, or gedatolisib in combination with fulvestrant, outweigh its risks.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →